{"id":3520,"date":"2018-11-01T17:58:54","date_gmt":"2018-11-01T12:28:54","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3520"},"modified":"2021-07-24T12:57:06","modified_gmt":"2021-07-24T07:27:06","slug":"the-business-cocktail-43","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43","title":{"rendered":"Gilead remunerates; Roche taps Halozyme\u2019s drug delivery tech; Orchard Therapeutics prices its IPO"},"content":{"rendered":"<p><strong>Gilead remunerates USD 50 Million to collaborate with synthetic lethality startup Tango<\/strong><\/p>\n<p><strong>Gilead<\/strong> is remunerating <strong>USD 50 million<\/strong> upfront to enter into an immuno-oncology collaboration with Massachusetts-based <strong>Tango Therapeutics<\/strong>. The deal provides Gilead with the option to receive the worldwide rights to five targets discovered and validated by Tango. The company, a Third Rock Ventures-backed startup that uses <strong>CRISPR<\/strong> and other tools to discover synthetic lethal gene pairs. The approach had opened more targets than the startup, driving it to enter into discussions with potential partners.<\/p>\n<p><strong>Roche taps Halozyme\u2019s drug delivery tech for up to USD 520 Million<\/strong><\/p>\n<p><strong>Roche and Halozyme<\/strong> with their initial collaboration around the latter\u2019s <strong>Enhanze<\/strong> drug delivery platform, Roche is\u00a0licensing\u00a0it again for three new targets. Roche is remunerating <strong>USD 25 million<\/strong> up front, but Halozyme will receive between USD160 million and USD165 million in milestones for each target\u2014up to <strong>USD 495 million<\/strong> in total.\u00a0The Big Pharma will develop a new, undisclosed clinical-stage therapeutic target.<\/p>\n<p><strong>Orchard Therapeutics prices its IPO<\/strong><\/p>\n<p><strong>Orchard Therapeutics<\/strong>\u00a0sets\u00a0its IPO at USD 14 a share, raising <strong>USD 200 million<\/strong> and exceeding the <strong>USD 173 million<\/strong> goals that it has set earlier. The funds will bankroll the essential trials and regulatory filings for three gene therapies in the U.S. and Europe.\u00a0The IPO haul will also progress OTL-102, for the X-linked chronic granulomatous disease. The earlier-stage programs of Orchard in Sanfillipo syndrome and beta thalassemia will benefit too.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead remunerates USD 50 Million to collaborate with synthetic lethality startup Tango Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics. The deal provides Gilead with the option to receive the worldwide rights to five targets discovered and validated by Tango. The company, a Third Rock Ventures-backed [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3483,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[109,2067,794,1728,1971,2066,2065],"industry":[17225],"therapeutic_areas":[17235,17233,17234],"class_list":["post-3520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-beta-thalassemia","tag-enhanze","tag-gilead","tag-ipo","tag-orchard-therapeutics","tag-roche-and-halozyme","tag-tango-therapeutics","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-hematological-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead remunerates; Roche taps Halozyme\u2019s drug delivery tech<\/title>\n<meta name=\"description\" content=\"Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead remunerates; Roche taps Halozyme\u2019s drug delivery tech\" \/>\n<meta property=\"og:description\" content=\"Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-01T12:28:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1547\" \/>\n\t<meta property=\"og:image:height\" content=\"943\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead remunerates; Roche taps Halozyme\u2019s drug delivery tech","description":"Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43","og_locale":"en_US","og_type":"article","og_title":"Gilead remunerates; Roche taps Halozyme\u2019s drug delivery tech","og_description":"Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics.","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-11-01T12:28:54+00:00","article_modified_time":"2021-07-24T07:27:06+00:00","og_image":[{"width":1547,"height":943,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43","name":"Gilead remunerates; Roche taps Halozyme\u2019s drug delivery tech","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","datePublished":"2018-11-01T12:28:54+00:00","dateModified":"2021-07-24T07:27:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-43#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault.jpg","width":1547,"height":943,"caption":"Gilead"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022444\/maxresdefault-300x183.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">beta-thalassemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Enhanze<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orchard Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche and Halozyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tango Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">beta-thalassemia<\/span>","<span class=\"advgb-post-tax-term\">Enhanze<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Orchard Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Roche and Halozyme<\/span>","<span class=\"advgb-post-tax-term\">Tango Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 1, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 1, 2018 5:58 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3520"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3520\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3483"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3520"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3520"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}